Few youths with sickle cell anemia (SCA) receive hydroxyurea despite national guidelines recommending its use, according to a study published online March 24 in JAMA Network Open.
Mar 28, 2023
0
0
Hydroxycarbamide (INN) or hydroxyurea (brand names include Hydrea and Droxia) is an antineoplastic drug, first synthesized in 1869, used in myeloproliferative disorders, specifically polycythemia vera and essential thrombocythemia. It is also used to reduce the rate of painful attacks in sickle-cell disease and has antiretroviral properties in diseases such as AIDS.
This text uses material from Wikipedia, licensed under CC BY-SA
